These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23150551)

  • 21. Lessons learned from Myc/Max/Mad knockout mice.
    Pirity M; Blanck JK; Schreiber-Agus N
    Curr Top Microbiol Immunol; 2006; 302():205-34. PubMed ID: 16620030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYC needs MNT.
    Link JM; Hurlin PJ
    Cell Cycle; 2013 Feb; 12(3):385-6. PubMed ID: 23324353
    [No Abstract]   [Full Text] [Related]  

  • 23. Analysis of Myc/Max/Mad network members in adipogenesis: inhibition of the proliferative burst and differentiation by ectopically expressed Mad1.
    Pulverer B; Sommer A; McArthur GA; Eisenman RN; Lüscher B
    J Cell Physiol; 2000 Jun; 183(3):399-410. PubMed ID: 10797315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mnt: master regulator of the Max network.
    Nilsson JA; Cleveland JL
    Cell Cycle; 2004 May; 3(5):588-90. PubMed ID: 15107624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival.
    Vasilevsky NA; Ruby CE; Hurlin PJ; Weinberg AD
    Eur J Immunol; 2011 Apr; 41(4):1024-34. PubMed ID: 21400495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT.
    Zhang Z; Sun H; Dai H; Walsh RM; Imakura M; Schelter J; Burchard J; Dai X; Chang AN; Diaz RL; Marszalek JR; Bartz SR; Carleton M; Cleary MA; Linsley PS; Grandori C
    Cell Cycle; 2009 Sep; 8(17):2756-68. PubMed ID: 19652553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetics of myc-max-mad gene expression during hepatocyte proliferation in vivo: Differential regulation of mad family and stress-mediated induction of c-myc.
    Mauleon I; Lombard MN; Muñoz-Alonso MJ; Cañelles M; Leon J
    Mol Carcinog; 2004 Feb; 39(2):85-90. PubMed ID: 14750213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation.
    Lin CJ; Cencic R; Mills JR; Robert F; Pelletier J
    Cancer Res; 2008 Jul; 68(13):5326-34. PubMed ID: 18593934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MNT inhibits the migration of human hepatocellular carcinoma SMMC7721 cells.
    Wu J; Zhou Q; Wang Y; Zhou X; Li J
    Biochem Biophys Res Commun; 2012 Feb; 418(1):93-7. PubMed ID: 22244890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
    Smith AG; Popov N; Imreh M; Axelson H; Henriksson M
    J Cell Biochem; 2004 Aug; 92(6):1282-95. PubMed ID: 15258910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc.
    Yang W; Shen J; Wu M; Arsura M; FitzGerald M; Suldan Z; Kim DW; Hofmann CS; Pianetti S; Romieu-Mourez R; Freedman LP; Sonenshein GE
    Oncogene; 2001 Mar; 20(14):1688-702. PubMed ID: 11313917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MNT suppresses T cell apoptosis via BIM and is critical for T lymphomagenesis.
    Nguyen HV; Vandenberg CJ; Robati MR; Ng AP; Cory S
    Cell Death Differ; 2023 Apr; 30(4):1018-1032. PubMed ID: 36755068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression.
    Yang H; Li TW; Peng J; Tang X; Ko KS; Xia M; Aller MA
    Gastroenterology; 2011 Jul; 141(1):378-88, 388.e1-4. PubMed ID: 21440549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of apoptosis by the c-Myc helix-loop-helix/leucine zipper domain in mouse 3T3-L1 fibroblasts.
    Kohlhuber F; Hermeking H; Graessmann A; Eick D
    J Biol Chem; 1995 Dec; 270(48):28797-805. PubMed ID: 7499403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sin3 corepressor function in Myc-induced transcription and transformation.
    Harper SE; Qiu Y; Sharp PA
    Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8536-40. PubMed ID: 8710905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteomic discovery of Max as a novel interacting partner of C/EBPalpha: a Myc/Max/Mad link.
    Zada AA; Pulikkan JA; Bararia D; Geletu M; Trivedi AK; Balkhi MY; Hiddemann WD; Tenen DG; Behre HM; Behre G
    Leukemia; 2006 Dec; 20(12):2137-46. PubMed ID: 17082780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The c-MYC oncoprotein as a treatment target in cancer and other disorders of cell growth.
    Pelengaris S; Khan M
    Expert Opin Ther Targets; 2003 Oct; 7(5):623-42. PubMed ID: 14498825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif.
    Hurlin PJ; Steingrìmsson E; Copeland NG; Jenkins NA; Eisenman RN
    EMBO J; 1999 Dec; 18(24):7019-28. PubMed ID: 10601024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins.
    Cerni C; Bousset K; Seelos C; Burkhardt H; Henriksson M; Lüscher B
    Oncogene; 1995 Aug; 11(3):587-96. PubMed ID: 7630643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. micRo-manageMeNT of MYC during hypoxia.
    Morrish F
    Cell Cycle; 2009 Sep; 8(18):2865. PubMed ID: 19736515
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.